arrow_back Back to App

Shortening Biologic Drug Exclusivity: Lower Prices, Increased Access.

This act shortens the exclusivity period for new brand-name biologic drugs from 12 to 5 years. This means that more affordable versions of these drugs could enter the market much sooner, potentially lowering treatment costs and increasing access to vital therapies for citizens.
Key points
Biologic Drugs: The period during which only one company can sell a new biologic drug will be reduced from 12 to 5 years.
Lower Prices: The faster entry of more affordable alternatives (biosimilar drugs) could reduce drug costs for patients and healthcare systems.
Increased Access: More companies will be able to produce and sell these drugs, potentially improving their availability in the market.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_7828
Sponsor: Rep. Schakowsky, Janice D. [D-IL-9]
Process start date: 2022-05-18
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

PRICED Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_7828.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-05-18.

What are the main provisions?

Key points include:

  • Biologic Drugs: The period during which only one company can sell a new biologic drug will be reduced from 12 to 5 years.
  • Lower Prices: The faster entry of more affordable alternatives (biosimilar drugs) could reduce drug costs for patients and healthcare systems.
  • Increased Access: More companies will be able to produce and sell these drugs, potentially improving their availability in the market.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Schakowsky, Janice D. [D-IL-9].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health